论文部分内容阅读
目的:了解人微小病毒B19(HPVB19)与成人血液疾病的关系。方法:采用ELISA法检测2004年1月-2005年1月在我科住院的139例血液病患者血清中HPVB19抗体IgG、IgM;与正常对照35例进行分析。结果:2组数据方差齐性Levene检验结果显示方差不齐,相应得到2组人HPVB19抗体IgG和IgM,差异均有统计学意义(均P<0．01)。提示血液病患者HPVB19抗体IgG、IgM都高于正常人。免疫性血液疾病(36．67％)及血液肿瘤(29．51％)HPVB19感染率较高。而再生障碍性贫血(18．18％)、缺铁性贫血(12．5％)HPVB19感染率则较低。结论:对于免疫性血液疾病及血液肿瘤,当出现治疗效果不显著时,建议检测HPVB19,对有HPVB19感染患者,加用免疫球蛋白治疗,以提高疗效。
Objective: To understand the relationship between human parvovirus B19 (HPVB19) and adult blood diseases. Methods: Serum samples of 139 patients with hematological diseases who were hospitalized in our department from January 2004 to January 2005 were enrolled in this study. Serum IgG and IgM were detected by ELISA in 35 patients. Results: The results of Levene test showed that the variance of two groups of data was different, and the IgG and IgM of two groups of human antibodies were obtained. The difference was statistically significant (all P <0.01). Prompt blood disease patients with HPVB19 antibodies IgG, IgM are higher than normal. Immune blood disease (36.67%) and hematological malignancies (29.51%) had a higher infection rate of HPV19. Aplastic anemia (18.18%), iron deficiency anemia (12.5%) HPVB19 infection rate is lower. Conclusion: For the treatment of autoimmune hematological diseases and hematological malignancies, it is recommended to detect HPVB19 when the treatment effect is not obvious, and immunoglobulin is added to patients with HPVB19 infection to improve the curative effect.